Literature DB >> 21766476

Competition by inhibitory oligonucleotides prevents binding of CpG to C-terminal TLR9.

Ana M Avalos1, Hidde L Ploegh.   

Abstract

TLR9 recognizes unmethylated CpG-containing DNA commonly found in bacteria. Synthetic oligonucleotides containing CpG-motifs (CpG ODNs) recapitulate the activation of TLR9 by microbial DNA, whereas inversion of the CG dinucleotide within the CpG motif to GC (GpC ODNs) renders such ODNs inactive. This difference cannot be attributed to binding of ODNs to the full-length TLR9 ectodomain, as both CpG and GpC ODNs bind comparably. Activation of murine TLR9 requires cleavage into an active C-terminal fragment, which binds CpG robustly. We therefore compared the ability of CpG and GpC ODNs to bind to full-length and C-terminal TLR9, and their impact on the cleavage of TLR9. We found that CpG binds better to C-terminal TLR9 when compared with GpC, despite comparably low binding of both ODNs to full-length TLR9. Neither CpG nor GpC ODNs affected TLR9 cleavage in murine RAW 264.7 cells stably expressing TLR9-Myc. Inhibitory ODNs (IN-ODNs) block TLR9 signaling, but how they do so remains unclear. We show here that inhibitory ODNs do not impede TLR9 cleavage but bind to C-terminal TLR9 preferentially, and thereby compete for CpG ODN binding both in RAW cells and in TLR9-deficient cells transduced with TLR9-Myc. Ligand binding to C-terminal fragment thus determines the outcome of activation through TLR9.
Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21766476      PMCID: PMC3746339          DOI: 10.1002/eji.201141563

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  31 in total

1.  A Toll-like receptor recognizes bacterial DNA.

Authors:  H Hemmi; O Takeuchi; T Kawai; T Kaisho; S Sato; H Sanjo; M Matsumoto; K Hoshino; H Wagner; K Takeda; S Akira
Journal:  Nature       Date:  2000-12-07       Impact factor: 49.962

2.  Identification of an N-terminal recognition site in TLR9 that contributes to CpG-DNA-mediated receptor activation.

Authors:  Mirjam E Peter; Andriy V Kubarenko; Alexander N R Weber; Alexander H Dalpke
Journal:  J Immunol       Date:  2009-06-15       Impact factor: 5.422

3.  TLR9 blockade inhibits activation of diabetogenic CD8+ T cells and delays autoimmune diabetes.

Authors:  Yiqun Zhang; Andrew S Lee; Afshin Shameli; Xuan Geng; Diane Finegood; Pere Santamaria; Jan P Dutz
Journal:  J Immunol       Date:  2010-04-14       Impact factor: 5.422

4.  CpG stimulation of primary mouse B cells is blocked by inhibitory oligodeoxyribonucleotides at a site proximal to NF-kappaB activation.

Authors:  P Lenert; L Stunz; A K YI; A M Krieg; R F Ashman
Journal:  Antisense Nucleic Acid Drug Dev       Date:  2001-08

5.  A comparative survey of the hydrolytic enzymes of ectoparasitic and free-living mites.

Authors:  A J Nisbet; P F Billingsley
Journal:  Int J Parasitol       Date:  2000-01       Impact factor: 3.981

6.  Phosphorothioate backbone modification modulates macrophage activation by CpG DNA.

Authors:  D P Sester; S Naik; S J Beasley; D A Hume; K J Stacey
Journal:  J Immunol       Date:  2000-10-15       Impact factor: 5.422

Review 7.  Classification, mechanisms of action, and therapeutic applications of inhibitory oligonucleotides for Toll-like receptors (TLR) 7 and 9.

Authors:  Petar S Lenert
Journal:  Mediators Inflamm       Date:  2010-05-18       Impact factor: 4.711

8.  Critical role for asparagine endopeptidase in endocytic Toll-like receptor signaling in dendritic cells.

Authors:  Fernando E Sepulveda; Sophia Maschalidi; Renaud Colisson; Lea Heslop; Cristina Ghirelli; Emna Sakka; Ana-Maria Lennon-Duménil; Sebastian Amigorena; Lucien Cabanie; Bénédicte Manoury
Journal:  Immunity       Date:  2009-10-29       Impact factor: 31.745

9.  Proteolytic cleavage in an endolysosomal compartment is required for activation of Toll-like receptor 9.

Authors:  Boyoun Park; Melanie M Brinkmann; Eric Spooner; Clarissa C Lee; You-Me Kim; Hidde L Ploegh
Journal:  Nat Immunol       Date:  2008-10-19       Impact factor: 25.606

10.  The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor.

Authors:  Sarah E Ewald; Bettina L Lee; Laura Lau; Katherine E Wickliffe; Guo-Ping Shi; Harold A Chapman; Gregory M Barton
Journal:  Nature       Date:  2008-09-28       Impact factor: 49.962

View more
  14 in total

1.  Adeno-associated virus activates an innate immune response in normal human cells but not in osteosarcoma cells.

Authors:  Leila N Laredj; Peter Beard
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

2.  Type I interferons: diversity of sources, production pathways and effects on immune responses.

Authors:  Melissa Swiecki; Marco Colonna
Journal:  Curr Opin Virol       Date:  2011-11-25       Impact factor: 7.090

3.  Proteolytic processing regulates Toll-like receptor 3 stability and endosomal localization.

Authors:  Rongsu Qi; Divyendu Singh; C Cheng Kao
Journal:  J Biol Chem       Date:  2012-08-03       Impact factor: 5.157

Review 4.  Modulating toll-like receptor 7 and 9 responses as therapy for allergy and autoimmunity.

Authors:  Damir Matesic; Aleksander Lenert; Petar Lenert
Journal:  Curr Allergy Asthma Rep       Date:  2012-02       Impact factor: 4.806

5.  Dual Toll-Like Receptor Targeting Liposomal Spherical Nucleic Acids.

Authors:  Jennifer R Ferrer; Jason A Wertheim; Chad A Mirkin
Journal:  Bioconjug Chem       Date:  2019-03-04       Impact factor: 4.774

6.  Mannose receptor 1 mediates cellular uptake and endosomal delivery of CpG-motif containing oligodeoxynucleotides.

Authors:  Annie Park Moseman; E Ashley Moseman; Stephen Schworer; Irina Smirnova; Tatyana Volkova; Ulrich von Andrian; Alexander Poltorak
Journal:  J Immunol       Date:  2013-11-01       Impact factor: 5.422

Review 7.  Role of Mitochondria-Derived Danger Signals Released After Injury in Systemic Inflammation and Sepsis.

Authors:  Kiyoshi Itagaki; Ingred Riça; Barbora Konecna; Hyo In Kim; Jinbong Park; Elzbieta Kaczmarek; Carl J Hauser
Journal:  Antioxid Redox Signal       Date:  2021-05-25       Impact factor: 7.468

8.  Guanine-modified inhibitory oligonucleotides efficiently impair TLR7- and TLR9-mediated immune responses of human immune cells.

Authors:  Franziska Römmler; Monika Hammel; Anna Waldhuber; Tina Müller; Marion Jurk; Eugen Uhlmann; Hermann Wagner; Jörg Vollmer; Thomas Miethke
Journal:  PLoS One       Date:  2015-02-19       Impact factor: 3.240

9.  In vivo TLR9 inhibition attenuates CpG-induced myocardial dysfunction.

Authors:  O Boehm; P Markowski; M van der Giet; V Gielen; A Kokalova; C Brill; A Hoeft; G Baumgarten; R Meyer; P Knuefermann
Journal:  Mediators Inflamm       Date:  2013-04-10       Impact factor: 4.711

10.  The human papillomavirus type 16 E7 oncoprotein induces a transcriptional repressor complex on the Toll-like receptor 9 promoter.

Authors:  Uzma A Hasan; Claudia Zannetti; Peggy Parroche; Nadège Goutagny; Marine Malfroy; Guillaume Roblot; Christine Carreira; Ishraq Hussain; Martin Müller; Joyce Taylor-Papadimitriou; Didier Picard; Bakary S Sylla; Giorgio Trinchieri; Ruslan Medzhitov; Massimo Tommasino
Journal:  J Exp Med       Date:  2013-06-10       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.